X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biospace.com/article/releases/recce-pharmaceuticals-completes-5-000-recce-327-doses-a-week-under-good-manufacturing-practice-gmp-/
https://www.globenewswire.com/news-release/2024/04/17/2864456/0/en/Recce-Pharmaceuticals-Completes-5-000-RECCE-327-Doses-a-Week-under-Good-Manufacturing-Practice-GMP.html
https://www.globenewswire.com/news-release/2024/04/10/2860702/0/en/Recce-Pharmaceuticals-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/10/2860434/0/en/Recce-Pharmaceuticals-Selected-by-UK-Government-Innovation-Agency-to-Participate-in-AMR-Mission-2024.html
https://www.globenewswire.com/news-release/2024/04/04/2857707/0/en/Recce-Pharmaceuticals-Granted-New-Patent-in-Israel-for-RECCE-Anti-Infectives.html
https://www.globenewswire.com/news-release/2024/03/22/2850913/0/en/Recce-Pharmaceuticals-Announces-RECCE-Trademark-Registered-in-Canada-Strengthening-Global-IP-Portfolio.html
https://www.globenewswire.com/news-release/2024/03/19/2848516/0/en/Recce-Pharmaceuticals-Completes-Dosing-Cohort-in-Phase-I-II-Trial-of-RECCE-327-for-Urinary-Tract-Infections-and-Urosepsis.html
https://www.globenewswire.com//news-release/2024/03/14/2846219/0/en/Recce-Pharmaceuticals-Doses-Next-Cohort-in-Phase-I-II-Trial-of-RECCE-327-for-Urinary-Tract-Infections-and-Urosepsis.html
https://www.globenewswire.com//news-release/2024/03/13/2845361/0/en/Recce-Pharmaceuticals-to-Present-at-the-American-Society-for-Clinical-Pharmacology-Therapeutics-ASCPT-2024-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/03/12/2844448/0/en/Recce-Pharmaceuticals-Receives-AUD-11-17-Million-Research-and-Development-R-D-Advance.html
Market Place
Share 
